Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faster aspart pharmacokinetics in Chinese patients with diabetes
NCT04698018Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2021
- Primary completion
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of faster-acting insulin aspart in type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the serum insulin aspart concentration-time curve from 0 to 30 minutes. Started Apr 2021; status: completed.
02
Drugs
faster-acting insulin aspart
03
Conditions
type 1 diabetes mellitus (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04698018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04698018.